Stocks · News reference
Filed: 2026-11-02 AccNo: 0001035267-26-000074 Size: 164 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The IEEE has officially recognized the "First Robotic Telepresence Surgery System," the technology licensed to Intuitive Surgical that became the da Vinci Surgical System, as an IEEE Milestone.
HSBC has updated its price target for Intuitive Surgical, Inc., raising it slightly from $391 to $392.
Revvity (RVTY) reported Q3 2026 adjusted EPS of $1.38, beating estimates by 7%, with revenues rising 4.3% to $728.9M. Life Sciences revenues climbed 10.7% driven by strong pharma and biotech demand. The company raised its 2026 pro forma EPS guidance to $5.40-$5.45 and revenue forecast to $2.86B, reflecting 6% total growth and 5% organic growth.
Fredrik Widman, Corporate Vice President and Financial Controller at Intuitive Surgical, exercised stock options and sold 5,448 shares of company stock.
Intuitive Surgical has announced the appointment of Humana executive Aaron Martin to its board of directors, effective January 1, 2027.
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.